Concepts and applications
🗓 mercredi 22 mai 2024
📍 Bordeaux, France
REGISTRATION DEADLINE: March 15, 2024
ORGANIZERS: Laurent DEBARBIEUX (Institut Pasteur, Paris), Rémy FROISSART (CNRS UMR 5290, Montpellier) and Frédéric LAURENT (Inserm U1111 – HCL, Lyon)
AIMS: To provide theoretical/practical knowledge in phage biology allowing participants
• to bring their input and research expertise into fighting on antibiotic resistance and treatment failures of chronic/recurrent infections
• to be involved into the renewal of phage therapy in France and Europe
CONTEXT OF PHAGE THERAPY
Fréderic LAURENT (Inserm U1111-HCL, FRA)
BIOLOGY OF BACTERIOPHAGES
Laurent DEBARBIEUX (Institut Pasteur, FRA), François ROUSSET (Weizmann Institute of Science, ISR) and Rémy FROISSART (CNRS UMR 5290, FRA)
THERAPEUTIC PHAGES: PREPARATIONS AND USE
Fabrice PIROT and Frédéric LAURENT (Hospices Civils de Lyon, FRA), Camille KOLENDA (Inserm U1111, FRA), Gregory RESCH (Centre hospitalier universitaire vaudois, CHE), Luis MELO (University of Minho, PRT) and Raphaël LAURENCEAU (Institut Pasteur, FRA)
REGULATORY FRAMEWORKS & EUROPEAN EXPERIENCES
Charlotte BRIVES (CNRS UMR 5116, FRA), Mzia KUTATELADZE (G. Eliava Institute of Bacteriophages, Microbiology and Virology, GEO), Jean-Paul PIRNAY (Hôpital militaire Reine Astrid, BEL) and Alexandre BLEIBTREU (APHP, FRA)
BACTERIOPHAGES IN ECOSYSTEMS
Luisa DE SORDI (Sorbonne University, FRA), Clara TORRES-BARCELÓ (INRAE, FRA) and Claire LE HENAFF (University of Bordeaux, FRA)
The technical part will introduce participants to the key steps of natural phage isolation, phage training, genetic analysis of phages, phage titration, and phage susceptibility testing. Participants will be initiated to the practical aspects of therapeutic phage production, purification, CQs, and pharmaceutical packaging. The technical part will end with a simulation of a phage laboratory set-up where a patient’s strain is received and the steps for a magistral preparation of a phage cocktail are implemented before human administration.
SELECTION: 8-12 trainees will be selected among Phase I participants.